^
    over1year
    CKD-516 potentiates the anti-cancer activity of docetaxel against epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer. (PubMed, Toxicol Res)
    In addition, docetaxel plus CKD-516 delayed tumor growth in-and extended the lifespan of-tumor-bearing mice. Thus, combination CKD-516 and docetaxel therapy could be used to treat EGFR-TKI-resistant NSCLC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • EGFR mutation • EGFR L858R • EGFR T790M • EGFR L858R + EGFR T790M • EGFR H1975
    |
    docetaxel • valecobulin (CKD-516)
    over3years
    Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma. (PubMed, BMC Cancer)
    Taken together, our data show that when used in combination, CKD-516 and IR can significantly enhance anti-tumor efficacy compared to monotherapy in lung cancer xenograft mice.
    Preclinical • Journal • Combination therapy
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • CD31 (Platelet and endothelial cell adhesion molecule 1)
    |
    MSLN positive • CD31 expression • HIF1A expression
    |
    valecobulin (CKD-516)